VA263-17-R-0448-002.docx

DOCX document 192 KB Posted

Attached to
Pathology and Laboratory Medicine Services
Solicitation number
VA26317R0448
Issued by

About this file

VA263-17-R-0448 VA263-17-R-0448.docx

View the file

Other files

File Type Posted
36C26318D0057-000.docx DOCX document
VA263-17-R-0448-00002000.docx DOCX document
VA263-17-R-0448-00001000.docx DOCX document
VA263-17-R-0448-003.pdf PDF
VA263-17-R-0448-004.pdf PDF
VA263-17-R-0448-005.pdf PDF
VA263-17-R-0448-001.docx DOCX document

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

VA263-17-R-0448

PAGE 1 OF

1. REQUISITION NO.

2. CONTRACT NO.

3. AWARD/EFFECTIVE DATE

4. ORDER NO.

5. SOLICITATION NUMBER

6. SOLICITATION ISSUE DATE

a. NAME

b. TELEPHONE NO. (No Collect Calls)

8. OFFER DUE DATE/LOCAL

TIME

9. ISSUED BY

CODE

10. THIS ACQUISITION IS

UNRESTRICTED OR

SET ASIDE:

% FOR:

SMALL BUSINESS

HUBZONE SMALL

BUSINESS

SERVICE-DISABLED

VETERAN-OWNED

SMALL BUSINESS

WOMEN-OWNED SMALL BUSINESS

(WOSB) ELIGIBLE UNDER THE WOMEN-OWNED

SMALL BUSINESS PROGRAM

EDWOSB

8(A)

NAICS:

SIZE STANDARD:

11. DELIVERY FOR FOB DESTINA-

TION UNLESS BLOCK IS

MARKED

SEE SCHEDULE

12. DISCOUNT TERMS

13a. THIS CONTRACT IS A

RATED ORDER UNDER

DPAS (15 CFR 700)

13b. RATING

14. METHOD OF SOLICITATION

RFQ

IFB

RFP

15. DELIVER TO

CODE

16. ADMINISTERED BY

CODE

17a. CONTRACTOR/OFFEROR

CODE

FACILITY CODE

18a. PAYMENT WILL BE MADE BY

CODE

TELEPHONE NO.

DUNS:

DUNS+4:

PHONE:

FAX:

17b. CHECK IF REMITTANCE IS DIFFERENT AND PUT SUCH ADDRESS IN OFFER 18b. SUBMIT INVOICES TO ADDRESS SHOWN IN BLOCK 18a UNLESS BLOCK BELOW IS CHECKED

SEE ADDENDUM

19.

20.

21.

22.

23.

24.

ITEM NO.

SCHEDULE OF SUPPLIES/SERVICES

QUANTITY

UNIT

UNIT PRICE

AMOUNT

(Use Reverse and/or Attach Additional Sheets as Necessary)

25. ACCOUNTING AND APPROPRIATION DATA

26. TOTAL AWARD AMOUNT (For Govt. Use Only) 27a. SOLICITATION INCORPORATES BY REFERENCE FAR 52.212-1, 52.212-4. FAR 52.212-3 AND 52.212-5 ARE ATTACHED. ADDENDA

ARE

ARE NOT ATTACHED.

27b. CONTRACT/PURCHASE ORDER INCORPORATES BY REFERENCE FAR 52.212-4. FAR 52.212-5 IS ATTACHED. ADDENDA

ARE

ARE NOT ATTACHED

28. CONTRACTOR IS REQUIRED TO SIGN THIS DOCUMENT AND RETURN _______________

29. AWARD OF CONTRACT: REF. ___________________________________ OFFER

COPIES TO ISSUING OFFICE. CONTRACTOR AGREES TO FURNISH AND

DATED ________________________________. YOUR OFFER ON SOLICITATION

DELIVER ALL ITEMS SET FORTH OR OTHERWISE IDENTIFIED ABOVE AND ON ANY

(BLOCK 5), INCLUDING ANY ADDITIONS OR CHANGES WHICH ARE

ADDITIONAL SHEETS SUBJECT TO THE TERMS AND CONDITIONS SPECIFIED

SET FORTH HEREIN IS ACCEPTED AS TO ITEMS:

30a. SIGNATURE OF OFFEROR/CONTRACTOR 31a. UNITED STATES OF AMERICA (SIGNATURE OF CONTRACTING OFFICER) 30b. NAME AND TITLE OF SIGNER (TYPE OR PRINT) 30c. DATE SIGNED 31b. NAME OF CONTRACTING OFFICER (TYPE OR PRINT) 31c. DATE SIGNED

AUTHORIZED FOR LOCAL REPRODUCTION

(REV. 2/2012)

PREVIOUS EDITION IS NOT USABLE

Prescribed by GSA - FAR (48 CFR) 53.212

7. FOR SOLICITATION

INFORMATION CALL:

STANDARD FORM 1449

OFFEROR TO COMPLETE BLOCKS 12, 17, 23, 24, & 30

SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL ITEMS

618-18-2-106-0041

VA263-17-R-0448

02-09 -2018 Daniel Vagts 651-293-3040 03-0 -2018

10:00AM CST

Department of Veterans Affairs NCO 23 - St Paul Attention: Daniel Vagts 316 Robert Street N.

St. Paul MN 55417 X 621511 $32.5 Million N/A X N/A X VA Medical Center Department of Veteran Affairs One Veterans Drive, Building 70 Minneapolis MN 55417 Department of Veterans Affairs NCO 23 - Minneapolis Attention: Daniel Vagts 316 Robert Street N.

St. Paul MN 55417

Y Department of Veterans Affairs Financial Services Center PO Box 149971 Austin TX 78714-9971 X See CONTINUATION Page Pathology and Laboratory Medicine Services for the Minneapolis VA Medical Center.

See Schedule of Items (pg.6) See Performance Work Statement (pg.21) See CONTINUATION Page X X X

ONE

Daniel Vagts Contracting Officer Table of Contents

SECTION A1
A.1 SF 1449 SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL ITEMS1
SECTION B - CONTINUATION OF SF 1449 BLOCKS4
B.1 CONTRACT ADMINISTRATION DATA4
B.2 LIMITATIONS ON SUBCONTRACTING-- MONITORING AND COMPLIANCE (JUN 2011)5
B.3 SUBCONTRACTING COMMITMENTS--MONITORING AND COMPLIANCE (JUN 2011)5
B.4 SCHEDULE OF ITEMS6
B.5 STATEMENT OF WORK21
SECTION C - CONTRACT CLAUSES30
C.1 52.212-4 CONTRACT TERMS AND CONDITIONS—COMMERCIAL ITEMS (MAY 2015)30
C.2 52.204-9 PERSONAL IDENTITY VERIFICATION OF CONTRACTOR PERSONNEL (JAN 2011)36
C.3 52.216-18 ORDERING (OCT 1995)37
C.4 52.216-19 ORDER LIMITATIONS (OCT 1995)37
C.5 52.216-22 INDEFINITE QUANTITY (OCT 1995)38
C.6 52.217-8 OPTION TO EXTEND SERVICES (NOV 1999)38
C.7 52.217-9 OPTION TO EXTEND THE TERM OF THE CONTRACT (MAR 2000)38
C.8 52.228-5 INSURANCE—WORK ON A GOVERNMENT INSTALLATION (JAN 1997)39
C.9 SUPPLEMENTAL INSURANCE REQUIREMENTS39
C.10 52.232-19 AVAILABILITY OF FUNDS FOR THE NEXT FISCAL YEAR (APR 1984)40
C.11 52.252-2 CLAUSES INCORPORATED BY REFERENCE (FEB 1998)40
C.12 VAAR 852.203-70 COMMERCIAL ADVERTISING (JAN 2008)40
C.13 VAAR 852.203-71 DISPLAY OF DEPARTMENT OF VETERAN AFFAIRS HOTLINE POSTER (DEC 1992)40
C.14 52.212-5 CONTRACT TERMS AND CONDITIONS REQUIRED TO IMPLEMENT STATUTES OR EXECUTIVE ORDERS—COMMERCIAL ITEMS (NOV 2017)41
SECTION D - CONTRACT DOCUMENTS, EXHIBITS, OR ATTACHMENTS49
D.1 List of Attachments49
SECTION E - SOLICITATION PROVISIONS50
E.1 52.212-1 INSTRUCTIONS TO OFFERORS—COMMERCIAL ITEMS (JAN 2017)50
E.2 52.209-7 INFORMATION REGARDING RESPONSIBILITY MATTERS (JUL 2013)57
E.3 52.216-1 TYPE OF CONTRACT (APR 1984)58
E.4 52.227-15 REPRESENTATION OF LIMITED RIGHTS DATA AND RESTRICTED COMPUTER SOFTWARE (DEC 2007)58
E.5 52.233-2 SERVICE OF PROTEST (SEP 2006)59
E.6 VAAR 852.209-70 ORGANIZATIONAL CONFLICTS OF INTEREST (JAN 2008)59
E.7 VAAR 852.215-70 SERVICE-DISABLED VETERAN-OWNED AND VETERAN-OWNED SMALL BUSINESS EVALUATION FACTORS (JUL 2016) (DEVIATION)60
E.8 VAAR 852.232-72 ELECTRONIC SUBMISSION OF PAYMENT REQUESTS (NOV 2012)60
E.9 VAAR 852.237-7 INDEMNIFICATION AND MEDICAL LIABILITY INSURANCE (JAN 2008)62
E.10 VAAR 852.237-70 CONTRACTOR RESPONSIBILITIES (APR 1984)63
E.11 VAAR 852.233-70 PROTEST CONTENT/ALTERNATIVE DISPUTE RESOLUTION (JAN 2008)63
E.12 VAAR 852.233-71 ALTERNATE PROTEST PROCEDURE (JAN 1998)64
E.13 VAAR 852.270-1 REPRESENTATIVES OF CONTRACTING OFFICERS (JAN 2008)64
E.14 VAAR 852.271-70 NONDISCRIMINATION IN SERVICES PROVIDED TO BENEFICIARIES (JAN 2008)64
E.15 52.252-1 SOLICITATION PROVISIONS INCORPORATED BY REFERENCE (FEB 1998)64
E.16 VAAR 852.252-70 SOLICITATION PROVISIONS OR CLAUSES INCORPORATED BY REFERENCE (JAN 2008)65
E.17 52.212-2EVALUATION—COMMERCIAL ITEMS (OCT 2014)66
E.18 52.212-3 OFFEROR REPRESENTATIONS AND CERTIFICATIONS—COMMERCIAL ITEMS (NOV 2017)68

SECTION B - CONTINUATION OF SF 1449 BLOCKS

B.1 CONTRACT ADMINISTRATION DATA

(continuation from Standard Form 1449, block 18A.)

1. Contract Administration: All contract administration matters will be handled by the following individuals:

a. CONTRACTOR:

b. GOVERNMENT: Contracting Officer 36C618 Department of Veterans Affairs NCO 23 - St Paul Attention: Daniel Vagts 316 Robert Street N.

St. Paul MN 55417

2. CONTRACTOR REMITTANCE ADDRESS: All payments by the Government to the contractor will be made in accordance with:

[X]
52.232-33, Payment by Electronic Funds Transfer—System For Award Management, or
[]
52.232-36, Payment by Third Party

3. INVOICES: Invoices shall be submitted in arrears:

a. Quarterly[]
b. Semi-Annually[]
c. Other[X] MONTHLY

4. GOVERNMENT INVOICE ADDRESS: All Invoices from the contractor shall be submitted electronically in accordance with VAAR Clause 852.232-72 Electronic Submission of Payment Requests.

Department of Veterans Affairs Financial Services Center PO Box 149971 Austin TX 78714-9971 ACKNOWLEDGMENT OF AMENDMENTS: The offeror acknowledges receipt of amendments to the Solicitation numbered and dated as follows:

AMENDMENT NO
DATE

Page 1 of Page 1 of

B.2 LIMITATIONS ON SUBCONTRACTING-- MONITORING AND COMPLIANCE (JUN 2011)

This solicitation includes FAR 52.219-4 Notice of Price Evaluation Preference for Hub Zone Small Business Concerns. Accordingly, any contract resulting from this solicitation will include this clause. The contractor is advised in performing contract administration functions, the CO may use the services of a support contractor(s) retained by VA to assist in assessing the contractor's compliance with the limitations on subcontracting or percentage of work performance requirements specified in the clause. To that end, the support contractor(s) may require access to contractor's offices where the contractor's business records or other proprietary data are retained and to review such business records regarding the contractor's compliance with this requirement. All support contractors conducting this review on behalf of VA will be required to sign an “Information Protection and Non-Disclosure and Disclosure of Conflicts of Interest Agreement” to ensure the contractor's business records or other proprietary data reviewed or obtained in the course of assisting the CO in assessing the contractor for compliance are protected to ensure information or data is not improperly disclosed or other impropriety occurs. Furthermore, if VA determines any services the support contractor(s) will perform in assessing compliance are advisory and assistance services as defined in FAR 2.101, Definitions, the support contractor(s) must also enter into an agreement with the contractor to protect proprietary information as required by FAR 9.505-4, obtaining access to proprietary information, paragraph (b). The contractor is required to cooperate fully and make available any records as may be required to enable the CO to assess the contractor's compliance with the limitations on subcontracting or percentage of work performance requirement.

VA263-15-R-0860

(End of Clause)

Page 1 of

Page 1 of

Page 1 of

B.3 SUBCONTRACTING COMMITMENTS--MONITORING AND COMPLIANCE (JUN 2011)

This solicitation includes VAAR 852.215-70, Service-Disabled Veteran-Owned and Veteran-Owned Small Business Evaluation Factors, and VAAR 852.215-71, Evaluation Factor Commitments. Accordingly, any contract resulting from this solicitation will include these clauses. The contractor is advised in performing contract administration functions, the CO may use the services of a support contractor(s) to assist in assessing contractor compliance with the subcontracting commitments incorporated into the contract. To that end, the support contractor(s) may require access to the contractor's business records or other proprietary data to review such business records regarding contract compliance with this requirement. All support contractors conducting this review on behalf of VA will be required to sign an “Information Protection and Non-Disclosure and Disclosure of Conflicts of Interest Agreement” to ensure the contractor's business records or other proprietary data reviewed or obtained in the course of assisting the CO in assessing the contractor for compliance are protected to ensure information or data is not improperly disclosed or other impropriety occurs. Furthermore, if VA determines any services the support contractor(s) will perform in assessing compliance are advisory and assistance services as defined in FAR 2.101, Definitions, the support contractor(s) must also enter into an agreement with the contractor to protect proprietary information as required by FAR 9.505-4, obtaining access to proprietary information, paragraph (b). The contractor is required to cooperate fully and make available any records as may be required to enable the CO to assess the contractor compliance with the subcontracting commitments.

B.4 SCHEDULE OF ITEMS

Contractor shall provide the following Pathology and Laboratory Medicine Services to the U.S. Department of Veterans Affairs Medical Center, Minneapolis MN. The offeror’s prices shall include all required labor, equipment, supplies, shipping/courier services and overhead costs as needed to meet the requirements listed in the Schedule of Items and Statement of Work. Prices as quoted shall be firm-fixed prices for the period specified.

BASE YEAR:

Item #
CPT CODE
Description
Qty
Price
Extended Amount
0001
#86618
Lyme disease serology
20
0002
#86617 x 2
Lyme blot (if appropriate)
20
0003
#88365
Histoplasma-In-Situ Hybridization
2
0004
#87385
Histoplasma Antigen, Serum
2
0005
#87385
Histoplasma Antigen, Urine
75
0006
#87385
Histoplasma Antigen, EIA, Bronchial Wash/Pericardial fluid
2
0007
#87385
Histoplasma Antigen, Spinal fluid
2
0008
#85557
Osmotic Fragility Erythrocytes
5
0009
#86790 x 2
Hantavirus Antibody, IgG, IgM with Reflex to Confirmation
4
0010
#86790
Hantavirus Antibody, IgG confirmation
2
0011
#86790
Hantavirus Antibody, IgM Confirmation
2
0012
#86635 x 3
Coccidioides Antibody, CSF
2
0013
#82657
Thiopurine Methyltransferase, RBC
100
0014
#83520
Anti-IgA,IgG, Serum
6
0015
#83520
Neuron Specific Enolase, CSF
5
0016
#82525
Copper, Liver tissue
4
0017
#83540
Iron, Liver tissue
5
0018
#80323
Nicotine and Metabolites, Urine
10
0019
#84305
Insulin-Like Growth Factor 1, Serum
2
0020
#86335
Beta-2 Transferrinin
5
0021
#85246
Von Willebrands Factor Antigen
15
0022
#85397
Von Willebrands Factor Activity
15
0023
#85245
Reflex to Ristocetin if indicated
15
0024
#85247
Von Willebrand Multimers (result ID 8844)
7
0025
#82024
ACTH Adenocorticotropic Hormone, Plasma
4
0026
#82652
1,25 Dihydroxyvitamin D, serum
100
0027
#80299
Infliximab Quant w Reflex to Antibodies to Infliximab,Serum
100
0028
#82657
Acid Alpha-Glucosidase, Blood Spot
3
0029
#83021
Hemoglobin Electrophoresis, A2 and F
2
0030
#83021
Hemoglobin Electrophoresis, B
2
0031
#83020
Quantitiation by Electrophoresis
5
0032
#83021
Quantitiation by HPLC
5
0033
#82664
IEF Confirms-Elecrophoresis,not Elsewhere specified
5
0034
#83068
Hemoglobin, Unstable, Blood
5
0035
#83789
Hemoglobin Variant by Mass Spectrometry (MS), Blood
5
0036
#81259
Hemoglobin electrophoresis, Molecular HBA1/HBA2
5
0037
#81364
Hemoglobin Electrophoresis, Molecular HBB
5
0038
#81363
Hemoglobin Electrophoresis, Molecular HBB
5
0039
#85660
Hemoglobin S, Screen, Blood
5
0040
#88184
Hemoglobin F, Red Blood Cell Distribution, Blood
5
0041
#87186
Antimicrobial Sensitivity, Nocardia Species
2
0042
#88184 x 2
Flow Cytometry/TC 1 Marker
5
0043
#88185 x 7
Flow Cytometry/TC Add-on
5
0044
#88188
Flow Cytometry Interp, 9-15 Markers (Reflex Test)
5
0045
#83788
MS - MS/MS
6
0046
#88380
Microdissection, Laser Capture
6
0047
#83605
D-Lactate, Plasma
2
0048
#87207
Microspidia Detection (Concentration)
2
0049
#87015
Microsporidia Detection Stain
2
0050
#83970
Parathyroid Hormone (PTH), Serum
5
0051
#84311
Adenosine Deaminase, Pericardial Fluid
2
0052
#84439
T4 (Thyroxine), Free, Serum
2
0053
#84443
Thyroid-Stimulating Hormone-Sensitive (s-TSH), Serum
2
0054
#84442
Thyroxine-Binding Globulin (TBG), Serum
2
0055
#87536
HIV-1 RNA Detection and Quantification, Plasma
10
0056
#87538
HIV-2 DNA/RNA Qualitative Real-Time PCR
10
0057
#86701
HIV-1 Antibody
5
0058
#86702
HIV-2 Antibody
5
0059
#86038
Antinuclear antibodies (ANA)
5
0060
#86039
if positive (if appropriate)
5
0061
#84402
Testosterone, free
2
0062
#84403
Total
2
0063
#83516
Mi-2
1
0064
#83516
PL-12
1
0065
#83516
PL-7
1
0066
#83516
EJ
1
0067
#83516
OJ
1
0068
#83516
SRP
1
0069
#83516
Ku
1
0070
#83516
U2 snRNP
1
0071
#83516
Anti-PM/Scl Ab
1
0072
#86235
Anti-Jo 1 Ab
1
0073
#80375
Azathioprine (Imuran) as 6-mercaptopurine
3
0074
#80299
Quantification of Drug
2
0075
#83516
Chemiluminescent Assay
2
0076
#82397
Antibodies to Inliximab (Reflex Test)
30
0077
#88321
Pathology Consultation, Outside case
20
0078
#88323
Pathology Consult, with Slide Prep
2
0079
#88342
Immunohistochemistry (each stain)
10
0080
#88312
Stain Group I (each stain)
2
0081
#81301
Microsatellite Instability Analysis
4
0082
#88341
MLH-1, Immunostain
2
0083
#88341
MLH-2 Immunostain
2
0084
#88341
MSH-6 Immunostain
2
0085
#88342
PMS-2 Immunostain
2
0086
#88381
Microdissection, manual
2
0087
#83912
Inerpretation and Report
2
0088
#83891
DNA Extraction, Highly purified (HPGDE)
2
0089
#83900 x2
Amp of pt nucleic acid, first 2 nucleic acid sequences
4
0090
#83901 x4
Amp of pt nucleic acid, Each additional nucleic acid
8
0091
#83909 x6
Separation/ID by High Resolution Technique
12
0092
#81340
T-Cell antigen receptor, beta
8
0093
#83909 x6
T-Cell receptor, gamma
8
0094
#81340
TCB
7
0095
#81342
TCG @
7
Volage-Gated Potassium Channel (VGKC) Antibody
5
0097
#87902
Hepatitis C Viral RNA NS5a Drug Resistance
1
0098
#87902
Hepatitis C Viral Rna NS3 Genotype
1
0099
#83912
Interpretation and Report
2
0100
#83891
DNA Extraction, Highly purified (HPGDE)
2
0101
#83900 x2
Amp of pt nucleic acid, first 2 nucleic acid sequences
4
0102
#83901 x4
Amp of pt nucleic acid, EA add nucleic acid sequence
8
0103
#83909 x4
Separation/ID by High Resolution Technique
8
0104
#83912
Interpretation and Report
2
0105
#83891
DNA Extraction, Highly purified (HPGDE)
2
0106
#83898 x2
Amp of pt nucleic acid,Single primer pair Each primer pair
4
0107
#83909 x2
Separation/ID by High Resolution Technique
4
0108
#81245
FLT3 ITD mutation detection
10
0109
#81246
FLLT3
10
0110
#83892
Enzymatic digestion
4
0111
#83909 x2
Separation/ID by High Resolution Technique
8
0112
#81210
BRAF
12
0113
#81275
KRAS
12
0114
#81403
HIRAS
12
0115
#81404
NRAS
12
0116
#81275
KRAS Gene, 7 Mutation Panel
5
0117
#88381
KRAS Gene, 7 Mutation Panel
5
0118
#88291
HER2 Amp Associated w Breast Cancer,FISH,Tissue
10
0119
#88271 x10
HER2 Amp Associated w Breast Cancer,FISH,Tissue
10
0120
#88274 x2
HER2 Amp Associated w Breast Cancer,FISH,Tissue
10
0121
#88275
HER2 Amp Associated w Breast Cancer,FISH,Tissue
10
0122
#88361
HER2, Breast,Quantitative Immunohistochemistry,Automated
10
0123
#88291
HER2 Amp Associated w Gastroesophageal Cancer,FISH,Tissue
36
0124
#88271 x10
HER2 Amp Associated w Gastroesophageal Cancer,FISH,Tissue
36
0125
#88274 x2
HER2 Amp Associated w Gastroesophageal Cancer,FISH,Tissue
36
0126
#88275
HER2 Amp Associated w Gastroesophageal Cancer,FISH,Tissue
36
0127
#88630
HER2 Gastric/Esophageal,semi quant. Immunhistochem,manu
36
0128
#88271 x2
DNA probe, each; first probe set
2
0129
#88291
Interpretation and report
2
0130
#88271 x2
DNA probe,EA (multiplied by number of add probe sets)
2
0131
#88274
Interphase in situ hybridization, less than 25 cells, EA probe
2
0132
#88274
Interphase in situ hybridization, 25 to 99 cells, EA probe set
2
0133
#88275
Interphase in situ hybridization, 100 to 300 cells, each probe
2
0134
#88630
HER2,Gastric/Esophageal,semi quant Immunohistochemistry
36
0135
#88361
HER2,breast,quantitative,immunohistochemistry, automated
10
0136
#81235
EGFR
2
0137
#88381
Microdissection, manual
2
0138
#81401
MYH Gene Analysis for Multiple Adenoma, Y165C and G382D
1
0139
#81403 x2
IDH1/2, Mutation Analysis
1
0140
#83520
Interleukin 2 Receptor (CD25), Soluble
1
0141
#88360 x2
Estrogen/Progesterone Receptor, Semi Quant. Immunohisto
10
0142
#81401
Hereditary Pancreatitis, Mutation (PRSS1)
2
0143
#81170
BAKDM (BCR/ABL), Tyrosine Kinase Inhib. Resist., Kinase scre
3
0144
#81287
MGMT(O-6-methylguanine-DNA methyltransferase
2
0145
#88381
Slide Review
2
0146
#81445
Melanoma Targeted Gene Panel by Next Generation, Tumor
5
0147
#88381
Microdissection, manual
5
0148
#81315
PML/RARA Quantitative, PCR
7
0149
#81201
APC
1
0150
#81228
Cytogenomic constitutional (genome-wide) microarray analy
1
0151
#81228
Hereditary Colon Cancer CGH Array
1
0152
#87798 x2
Tick-Borne Panel, Molecular Detection PCR, Blood
2
0153
#87798
Tropheryma whipplei, Molecular Dectection, PCR
2
0154
#86255
Antineuronal Nuc Aby, Type 1
10
0155
#86255
Antineuronal Nuc Aby, Type 2
10
0156
#86255
Antineuronal Nuc Aby, Type 3
10
0157
#86255
Anti-Glial Nuc Aby, Type 1
10
0158
#86255
Purkinje Cell Cyto Aby, Type 1
10
0159
#86255
Purkinje Cell Cyto Aby, Type 2
10
0160
#86256
Purkinje Cell Aby, Type TR
10
0161
#86256
Amphiphysin Aby, S
10
0162
#86256
CRMP-5-IgG
10
0163
#83520
Striational Muscle Aby
10
0164
#83519
P/Q Type Calcium Channel Aby
10
0165
#83519
N-Type Calcium Channel Aby
8
0166
#83519
Acetylcholine Receptor Binding Aby
8
0167
#83519
AChR Ganglinoic Neuronal Aby S
8
0168
#83519
Neuronal (V-G) K+ Channel Aby
8
0169
#84182
Ach recptor (muscle) modulating antibodies (if appropriate)
2
0170
#84182
CRMP-5-IgG Western Blot (if appropriate)
4
0171
#84182
Amphiphysin Western Blot confirmation (if appropriate)
2
0172
#84182
Paraneoplastic autoantibody Western Blot confirmation
2
0173
#86255
Neuromyelitis Optica (NMO) Autoantibody IgG, Serum
2
0174
#86341
GAD65 antibody assay (if appropriate)
2
0175
#86255
AGNA-1
2
0176
#86255
Amphiphysin
2
0177
#86255
ANNA-1
2
0178
#86255
ANNA-2
2
0179
#86255
ANNA-3
2
0180
#86255
CRMP-5-IgG
2
0181
#86255
PCA-1
2
0182
#86255
PCA-2
2
0183
#86255
PCA-Tr
2
0184
#86256
Antineuronal Nuc Aby, Type 1
10
0185
#86256
Antineuronal Nuc Aby, Type 2
10
0186
#86256
Anti-Glial Nuc Aby, Type 1
10
0187
#86256
Purkinje Cell Cyto Aby, Type 1
10
0188
#86256
Purkinje Cell Aby, Type 2
10
0189
#86256
Purkinje Cell Aby, Type TR
10
0190
#86256
Amphiphysin Aby, S
10
0191
#86256
CRMP-5-IgG
10
0192
#84182
Amphiphysin Western Blot confirmation (if appropriate)
2
0193
#83520
14-3-3 Protein, CSF
5
0194
#83519
Ach receptor (muscle) binding antibody
4
0195
#83519
AChR Ganglinoic Neuronal Antibody
4
0196
#83519
Neuronal VGKC anutoantibody
4
0197
#83519
N-type calcium channel antibody
4
0198
#83519
P/Q-type calcium channel antibody
4
0199
#82656
AGNA-1
4
0200
#82656
Amphiphysin
4
0201
#86255
GABAR-Ab
4
0202
#86255
NMDAR-Ab
4
0203
#86341
GAD65
4
0204
#83519
Ach receptor (muscle) binding antibody
2
0205
#83519
AChR ganglinoic neuronal antibody
2
0206
#83519
Neuronal VGKC anutoantibody
2
0207
#83519
N-type calcium channel antibody
2
0208
#83519
P/Q Type Calcium Channel Aby
2
0209
#86255
AGNA-1
2
0210
#86255
Amphiphysin
2
0211
#86255
AMPPAR-AB
2
0212
#86255
GABAR-Ab
2
0213
#86255
NMDAR-Ab
2
0214
#86341
GABD65
2
0215
#86255
LG1CS
2
0216
#86255
CS2CS
2
0217
#83519
Neuronal VGKC autoantibody
1
0218
#86256
AGNA-1
1
0219
#86256
Amphiphysin
1
0220
#84182
Amphiphysin Western Blot
1
0221
#84182
CRMP - Western blot confirmation
1
0222
#86255
NMO/AQP4-IgG CBA
1
0223
#86256
AMPAR-Ab titer
1
0224
#86256
GABAR-Ab titer
1
0225
#86256
NMDAR-Ab titer
1
0226
#82656
CRMP-5-IgG
1
0227
#81310
Nucleophosmin (NPM1) Mutation Analysis
1
0228
#81218
CEBPA CEPBA Mutations Gene Sequencing
5
0229
#81450
NGAML Next Generation Sequencing AML 8-gene panel
5
0230
#81219
CALR Calreticuling Mutation Analysis, Myeloproliferative Neo
5
0231
#81403
MPL Exon 10 Mutation Detection Varies
5
0232
#0027U
JAKXB Jak2 Exon 12 Other Non-V617F Mutation Dectection
2
0233
#88300
ANPAT - Anatomic Pathology Consultation, Wet Tissue (eye)
1
0234
#88302
ANPAT - Anatomic Pathology Consultation, Wet Tissue (eye)
1
0235
#88304
ANPAT - Anatomic Pathology Consultation, Wet Tissue (eye)
1
0236
#88305
ANPAT - Anatomic Pathology Consultation, Wet Tissue (eye)
1
0237
#88307
ANPAT - Anatomic Pathology Consultation, Wet Tissue (eye)
1
0238
#88309
ANPAT - Anatomic Pathology Consultation, Wet Tissue (eye)
1
0239
#81272 & #88381
KIT11
0
0240
#81272 & #88381
KIT13
0
0241
#81272 & #88381
KIT17
0
0242
GIST
GIST-Targeted Gene Panel by Next Gen Sequencing test code
1
0243
MELP
Melanoma panel test code MELP
5
0244
#88346 & 88350 x4
Cutaneous Direct immunofluorescences Assay (IFA) Biopsy
10
0245
#88346 & 88350
Cutaneous Direct immunofluorescences Antibodies (IgG) Ser
10

OPTION YEAR ONE:

Item #
CPT CODE
Description
Qty
Price
Extended Amount
1001
#86618
Lyme disease serology
20
1002
#86617 x 2
Lyme blot (if appropriate)
20
1003
#88365
Histoplasma-In-Situ Hybridization
2
1004
#87385
Histoplasma Antigen, Serum
2
1005
#87385
Histoplasma Antigen, Urine
75
1006
#87385
Histoplasma Antigen, EIA, Bronchial Wash/Pericardial fluid
2
1007
#87385
Histoplasma Antigen, Spinal fluid
2
1008
#85557
Osmotic Fragility Erythrocytes
5
1009
#86790 x 2
Hantavirus Antibody, IgG, IgM with Reflex to Confirmation
4
1010
#86790
Hantavirus Antibody, IgG confirmation
2
1011
#86790
Hantavirus Antibody, IgM Confirmation
2
1012
#86635 x 3
Coccidioides Antibody, CSF
2
1013
#82657
Thiopurine Methyltransferase, RBC
100
1014
#83520
Anti-IgA,IgG, Serum
6
1015
#83520
Neuron Specific Enolase, CSF
5
1016
#82525
Copper, Liver tissue
4
1017
#83540
Iron, Liver tissue
5
1018
#80323
Nicotine and Metabolites, Urine
10
1019
#84305
Insulin-Like Growth Factor 1, Serum
2
1020
#86335
Beta-2 Transferrinin
5
1021
#85246
Von Willebrands Factor Antigen
15
1022
#85397
Von Willebrands Factor Activity
15
1023
#85245
Reflex to Ristocetin if indicated
15
1024
#85247
Von Willebrand Multimers (result ID 8844)
7
1025
#82024
ACTH Adenocorticotropic Hormone, Plasma
4
1026
#82652
1,25 Dihydroxyvitamin D, serum
100
1027
#80299
Infliximab Quant w Reflex to Antibodies to Infliximab,Serum
100
1028
#82657
Acid Alpha-Glucosidase, Blood Spot
3
1029
#83021
Hemoglobin Electrophoresis, A2 and F
2
1030
#83021
Hemoglobin Electrophoresis, B
2
1031
#83020
Quantitiation by Electrophoresis
5
1032
#83021
Quantitiation by HPLC
5
1033
#82664
IEF Confirms-Elecrophoresis,not Elsewhere specified
5
1034
#83068
Hemoglobin, Unstable, Blood
5
1035
#83789
Hemoglobin Variant by Mass Spectrometry (MS), Blood
5
1036
#81259
Hemoglobin electrophoresis, Molecular HBA1/HBA2
5
1037
#81364
Hemoglobin Electrophoresis, Molecular HBB
5
1038
#81363
Hemoglobin Electrophoresis, Molecular HBB
5
1039
#85660
Hemoglobin S, Screen, Blood
5
1040
#88184
Hemoglobin F, Red Blood Cell Distribution, Blood
5
1041
#87186
Antimicrobial Sensitivity, Nocardia Species
2
1042
#88184 x 2
Flow Cytometry/TC 1 Marker
5
1043
#88185 x 7
Flow Cytometry/TC Add-on
5
1044
#88188
Flow Cytometry Interp, 9-15 Markers (Reflex Test)
5
1045
#83788
MS - MS/MS
6
1046
#88380
Microdissection, Laser Capture
6
1047
#83605
D-Lactate, Plasma
2
1048
#87207
Microspidia Detection (Concentration)
2
1049
#87015
Microsporidia Detection Stain
2
1050
#83970
Parathyroid Hormone (PTH), Serum
5
1051
#84311
Adenosine Deaminase, Pericardial Fluid
2
1052
#84439
T4 (Thyroxine), Free, Serum
2
1053
#84443
Thyroid-Stimulating Hormone-Sensitive (s-TSH), Serum
2
1054
#84442
Thyroxine-Binding Globulin (TBG), Serum
2
1055
#87536
HIV-1 RNA Detection and Quantification, Plasma
10
1056
#87538
HIV-2 DNA/RNA Qualitative Real-Time PCR
10
1057
#86701
HIV-1 Antibody
5
1058
#86702
HIV-2 Antibody
5
1059
#86038
Antinuclear antibodies (ANA)
5
1060
#86039
if positive (if appropriate)
5
1061
#84402
Testosterone, free
2
1062
#84403
Total
2
1063
#83516
Mi-2
1
1064
#83516
PL-12
1
1065
#83516
PL-7
1
1066
#83516
EJ
1
1067
#83516
OJ
1
1068
#83516
SRP
1
1069
#83516
Ku
1
1070
#83516
U2 snRNP
1
1071
#83516
Anti-PM/Scl Ab
1
1072
#86235
Anti-Jo 1 Ab
1
1073
#80375
Azathioprine (Imuran) as 6-mercaptopurine
3
1074
#80299
Quantification of Drug
2
1075
#83516
Chemiluminescent Assay
2
1076
#82397
Antibodies to Inliximab (Reflex Test)
30
1077
#88321
Pathology Consultation, Outside case
20
1078
#88323
Pathology Consult, with Slide Prep
2
1079
#88342
Immunohistochemistry (each stain)
10
1080
#88312
Stain Group I (each stain)
2
1081
#81301
Microsatellite Instability Analysis
4
1082
#88341
MLH-1, Immunostain
2
1083
#88341
MLH-2 Immunostain
2
1084
#88341
MSH-6 Immunostain
2
1085
#88342
PMS-2 Immunostain
2
1086
#88381
Microdissection, manual
2
1087
#83912
Inerpretation and Report
2
1088
#83891
DNA Extraction, Highly purified (HPGDE)
2
1089
#83900 x2
Amp of pt nucleic acid, first 2 nucleic acid sequences
4
1090
#83901 x4
Amp of pt nucleic acid, Each additional nucleic acid
8
1091
#83909 x6
Separation/ID by High Resolution Technique
12
1092
#81340
T-Cell antigen receptor, beta
8
1093
#83909 x6
T-Cell receptor, gamma
8
1094
#81340
TCB
7
1095
#81342
TCG @
7
Volage-Gated Potassium Channel (VGKC) Antibody
5
1097
#87902
Hepatitis C Viral RNA NS5a Drug Resistance
1
1098
#87902
Hepatitis C Viral Rna NS3 Genotype
1
1099
#83912
Interpretation and Report
2
1100
#83891
DNA Extraction, Highly purified (HPGDE)
2
1101
#83900 x2
Amp of pt nucleic acid, first 2 nucleic acid sequences
4
1102
#83901 x4
Amp of pt nucleic acid, EA add nucleic acid sequence
8
1103
#83909 x4
Separation/ID by High Resolution Technique
8
1104
#83912
Interpretation and Report
2
1105
#83891
DNA Extraction, Highly purified (HPGDE)
2
1106
#83898 x2
Amp of pt nucleic acid,Single primer pair Each primer pair
4
1107
#83909 x2
Separation/ID by High Resolution Technique
4
1108
#81245
FLT3 ITD mutation detection
10
1109
#81246
FLLT3
10
1110
#83892
Enzymatic digestion
4
1111
#83909 x2
Separation/ID by High Resolution Technique
8
1112
#81210
BRAF
12
1113
#81275
KRAS
12
1114
#81403
HIRAS
12
1115
#81404
NRAS
12
1116
#81275
KRAS Gene, 7 Mutation Panel
5
1117
#88381
KRAS Gene, 7 Mutation Panel
5
1118
#88291
HER2 Amp Associated w Breast Cancer,FISH,Tissue
10
1119
#88271 x10
HER2 Amp Associated w Breast Cancer,FISH,Tissue
10
1120
#88274 x2
HER2 Amp Associated w Breast Cancer,FISH,Tissue
10
1121
#88275
HER2 Amp Associated w Breast Cancer,FISH,Tissue
10
1122
#88361
HER2, Breast,Quantitative Immunohistochemistry,Automated
10
1123
#88291
HER2 Amp Associated w Gastroesophageal Cancer,FISH,Tissue
36
1124
#88271 x10
HER2 Amp Associated w Gastroesophageal Cancer,FISH,Tissue
36
1125
#88274 x2
HER2 Amp Associated w Gastroesophageal Cancer,FISH,Tissue
36
1126
#88275
HER2 Amp Associated w Gastroesophageal Cancer,FISH,Tissue
36
1127
#88630
HER2 Gastric/Esophageal,semi quant. Immunhistochem,manu
36
1128
#88271 x2
DNA probe, each; first probe set
2
1129
#88291
Interpretation and report
2
1130
#88271 x2
DNA probe,EA (multiplied by number of add probe sets)
2
1131
#88274
Interphase in situ hybridization, less than 25 cells, EA probe
2
1132
#88274
Interphase in situ hybridization, 25 to 99 cells, EA probe set
2
1133
#88275
Interphase in situ hybridization, 100 to 300 cells, each probe
2
1134
#88630
HER2,Gastric/Esophageal,semi quant Immunohistochemistry
36
1135
#88361
HER2,breast,quantitative,immunohistochemistry, automated
10
1136
#81235
EGFR
2
1137
#88381
Microdissection, manual
2
1138
#81401
MYH Gene Analysis for Multiple Adenoma, Y165C and G382D
1
1139
#81403 x2
IDH1/2, Mutation Analysis
1
1140
#83520
Interleukin 2 Receptor (CD25), Soluble
1
1141
#88360 x2
Estrogen/Progesterone Receptor, Semi Quant. Immunohisto
10
1142
#81401
Hereditary Pancreatitis, Mutation (PRSS1)
2
1143
#81170
BAKDM (BCR/ABL), Tyrosine Kinase Inhib. Resist., Kinase scre
3
1144
#81287
MGMT(O-6-methylguanine-DNA methyltransferase
2
1145
#88381
Slide Review
2
1146
#81445
Melanoma Targeted Gene Panel by Next Generation, Tumor
5
1147
#88381
Microdissection, manual
5
1148
#81315
PML/RARA Quantitative, PCR
7
1149
#81201
APC
1
1150
#81228
Cytogenomic constitutional (genome-wide) microarray analy
1
1151
#81228
Hereditary Colon Cancer CGH Array
1
1152
#87798 x2
Tick-Borne Panel, Molecular Detection PCR, Blood
2
1153
#87798
Tropheryma whipplei, Molecular Dectection, PCR
2
1154
#86255
Antineuronal Nuc Aby, Type 1
10
1155
#86255
Antineuronal Nuc Aby, Type 2
10
1156
#86255
Antineuronal Nuc Aby, Type 3
10
1157
#86255
Anti-Glial Nuc Aby, Type 1
10
1158
#86255
Purkinje Cell Cyto Aby, Type 1
10
1159
#86255
Purkinje Cell Cyto Aby, Type 2
10
1160
#86256
Purkinje Cell Aby, Type TR
10
1161
#86256
Amphiphysin Aby, S
10
1162
#86256
CRMP-5-IgG
10
1163
#83520
Striational Muscle Aby
10
1164
#83519
P/Q Type Calcium Channel Aby
10
1165
#83519
N-Type Calcium Channel Aby
8
1166
#83519
Acetylcholine Receptor Binding Aby
8
1167
#83519
AChR Ganglinoic Neuronal Aby S
8
1168
#83519
Neuronal (V-G) K+ Channel Aby
8
1169
#84182
Ach recptor (muscle) modulating antibodies (if appropriate)
2
1170
#84182
CRMP-5-IgG Western Blot (if appropriate)
4
1171
#84182
Amphiphysin Western Blot confirmation (if appropriate)
2
1172
#84182
Paraneoplastic autoantibody Western Blot confirmation
2
1173
#86255
Neuromyelitis Optica (NMO) Autoantibody IgG, Serum
2
1174
#86341
GAD65 antibody assay (if appropriate)
2
1175
#86255
AGNA-1
2
1176
#86255
Amphiphysin
2
1177
#86255
ANNA-1
2
1178
#86255
ANNA-2
2
1179
#86255
ANNA-3
2
1180
#86255
CRMP-5-IgG
2
1181
#86255
PCA-1
2
1182
#86255
PCA-2
2
1183
#86255
PCA-Tr
2
1184
#86256
Antineuronal Nuc Aby, Type 1
10
1185
#86256
Antineuronal Nuc Aby, Type 2
10
1186
#86256
Anti-Glial Nuc Aby, Type 1
10
1187
#86256
Purkinje Cell Cyto Aby, Type 1
10
1188
#86256
Purkinje Cell Aby, Type 2
10
1189
#86256
Purkinje Cell Aby, Type TR
10
1190
#86256
Amphiphysin Aby, S
10
1191
#86256
CRMP-5-IgG
10
1192
#84182
Amphiphysin Western Blot confirmation (if appropriate)
2
1193
#83520
14-3-3 Protein, CSF
5
1194
#83519
Ach receptor (muscle) binding antibody
4
1195
#83519
AChR Ganglinoic Neuronal Antibody
4
1196
#83519
Neuronal VGKC anutoantibody
4
1197
#83519
N-type calcium channel antibody
4
1198
#83519
P/Q-type calcium channel antibody
4
1199
#82656
AGNA-1
4
1200
#82656
Amphiphysin
4
1201
#86255
GABAR-Ab
4
1202
#86255
NMDAR-Ab
4
1203
#86341
GAD65
4
1204
#83519
Ach receptor (muscle) binding antibody
2
1205
#83519
AChR ganglinoic neuronal antibody
2
1206
#83519
Neuronal VGKC anutoantibody
2
1207
#83519
N-type calcium channel antibody
2
1208
#83519
P/Q Type Calcium Channel Aby
2
1209
#86255
AGNA-1
2
1210
#86255
Amphiphysin
2
1211
#86255
AMPPAR-AB
2
1212
#86255
GABAR-Ab
2
1213
#86255
NMDAR-Ab
2
1214
#86341
GABD65
2
1215
#86255
LG1CS
2
1216
#86255
CS2CS
2
1217
#83519
Neuronal VGKC autoantibody
1
1218
#86256
AGNA-1
1
1219
#86256
Amphiphysin
1
1220
#84182
Amphiphysin Western Blot
1
1221
#84182
CRMP - Western blot confirmation
1
1222
#86255
NMO/AQP4-IgG CBA
1
1223
#86256
AMPAR-Ab titer
1
1224
#86256
GABAR-Ab titer
1
1225
#86256
NMDAR-Ab titer
1
1226
#82656
CRMP-5-IgG
1
1227
#81310
Nucleophosmin (NPM1) Mutation Analysis
1
1228
#81218
CEBPA CEPBA Mutations Gene Sequencing
5
1229
#81450
NGAML Next Generation Sequencing AML 8-gene panel
5
1230
#81219
CALR Calreticuling Mutation Analysis, Myeloproliferative Neo
5
1231
#81403
MPL Exon 10 Mutation Detection Varies
5
1232
#0027U
JAKXB Jak2 Exon 12 Other Non-V617F Mutation Dectection
2
1233
#88300
ANPAT - Anatomic Pathology Consultation, Wet Tissue (eye)
1
1234
#88302
ANPAT - Anatomic Pathology Consultation, Wet Tissue (eye)
1
1235
#88304
ANPAT - Anatomic Pathology Consultation, Wet Tissue (eye)
1
1236
#88305
ANPAT - Anatomic Pathology Consultation, Wet Tissue (eye)
1
1237
#88307
ANPAT - Anatomic Pathology Consultation, Wet Tissue (eye)
1
1238
#88309
ANPAT - Anatomic Pathology Consultation, Wet Tissue (eye)
1
1239
#81272 & #88381
KIT11
0
1240
#81272 & #88381
KIT13
0
1241
#81272 & #88381
KIT17
0
1242
GIST
GIST-Targeted Gene Panel by Next Gen Sequencing test code
1
1243
MELP
Melanoma panel test code MELP
5
1244
#88346 & 88350 x4
Cutaneous Direct immunofluorescences Assay (IFA) Biopsy
10
1245
#88346 & 88350
Cutaneous Direct immunofluorescences Antibodies (IgG) Ser
10

SCHEDULE NOTES

Additional Tests It may occur that the VAMC laboratory will require a test not listed in the Schedule of Items but that is available from the contractor’s catalog of tests, or a new test becomes available that is not listed in the Schedule of Items. If a test is required that is not listed in the Schedule of Items, the VA and the contractor will negotiate a firm fixed price. The new tests will be added to the contract accordingly via a contract modification. These tests will be considered as part of the overall contract value and together with the other tests cannot exceed the total estimated contract value.

2. Estimated Quantities The quantities as listed in the “Schedule of Items” are estimated requirements for a twelve (12) month contract period with one (1) possible twelve (12) month options. The Government estimates, but does not guarantee, that the volume of purchases under this contract will be an estimated ceiling amount $985,000.00 for the entire 2-year contract period. The VAMC attempts to be as accurate as possible when providing estimated quantities, however, actual quantities required may vary from the quantities listed. The Government is obligated only to the extent of the minimum contract guarantee. During the period specified in FAR clause 52.216-18, ORDERING, the Government shall place orders totaling a minimum of $50,000.00 for a 12-month contract period.

3. Multiple Award It would be most advantageous to the Government to award to a contractor who can provide all of the line items as requested in the Schedule of Items. The Government may establish a single contract award for ALL line items in lieu of multiple contracts or may establish multiple contracts, whichever provides the best value to the VAMC.

B.5 STATEMENT OF WORK

1. SCOPE OF WORK

The US Department of Veterans Affairs Health Care System, Minneapolis, MN, hereinafter referred to as MVAHCS or VA, intends to issue a contract for “Complex Case Consultation and Testing for Anatomic Pathology, Neurology, and Infectious Disease” services for the Pathology and Laboratory Medicine Service (P&LMS) located at MVAHCS, One Veterans Drive, Minneapolis, MN 55417. All services provided shall be in accordance with the prices, terms and conditions of this contract.

Testing needs may consist of, but are not limited to, serological and in situ hybridization-based tests for infectious disease; quantitative tissue analysis for copper and iron; specialized neurological testing; screening for hereditary disorders such as hereditary non-polyposis colon carcinoma syndrome; hemoglobin electrophoresis; determination of erythrocyte, CSF, and serum enzyme levels; and consultation on complex anatomic pathology cases, including ophthalmologic, pulmonary and urologic pathology.

These services require a comprehensive academic medical center with extensive expertise across a wide range of surgical pathology disciplines and organ systems. The pathology department must include nationally recognized experts in a variety of areas of anatomic pathology, such as urologic, gastrointestinal, pulmonary, and soft tissue/ orthopedic pathology. In addition, the medical center must include a division or subdivision of ophthalmologic pathology, with specialized ophthalmologic pathologists.

The laboratory must be able to provide specialized neurology testing to include the following assays:

Neuromyelitis optica (NMO) Autoantibody, IgG, Serum Antineuronal Nuc Aby, Type 1 Antineuronal Nuc Aby, Type 2 Antineuronal Nuc Aby, Type 3 Anti-Glial Nuc Aby, Type 1 Purkinje Cell Cyto Aby, Type 1 Purkinje Cell Aby, Type 2 Purkinje Cell Aby, Type TR Amphiphysin Aby, S CRMP-6-IgG Striational Muscle Aby P/Q Type Calcium Channel Aby N-Type Calcium Channel Aby Acetylcholine Receptor Binding Aby AChR Ganglionic Neuronal Aby, S Neuronal (V-G) K+ Channel Aby CRMP-5-IgG Western Blot The contractor must be able to offer specialized testing for infectious disease, including in situ hybridization for histoplasma in tissue, and urinary histoplasma antigen.

Contractor shall provide laboratory testing services to include: List of tests with reference ranges, specimen requirements, processing and analysis of the specimen; and reporting of specimen results. Consultation regarding test selection, collection, transportation and result interpretation shall also be provided when required. The contractor must provide the following services:

Provide the following for transport of the specimens to include:

Lab test request forms (it is possible that vendor may need to customize forms to include information required by the VA).

Special instructions for handling of specimen.

Specimen collection supplies for specialized testing.

Analyze samples.

Contractor shall provide a monthly billing for tests provided each month following the month in which the service was delivered.

Contractor shall consult with VA Laboratory on test results by telephone as needed.

Provide the VA Laboratory with a means of communication to permit immediate inquiry regarding the status of a pending test.

A Laboratory User’s Manual or similar documentation will be provided to the VA Laboratory.

The manual shall include a list of all tests that the Contractor can provide along with the testing methodology used for each test, test reference ranges, length of time of testing, which days the test is run, and specimen requirements and any special handling required.

Provide the courier service for transport of specimens.

The MVAHCS Laboratory reserves the right to request the results of any proficiency testing that the contractor subscribes.

Licensing and Accreditation The Contractor’s shall assure compliance of all procedures and practices by the following accrediting agencies, and the facility and employees shall have all licenses, permits, accreditation, professional certifications and qualifications required by federal and state law to provide laboratory testing and consult services. This includes:

Accreditation by the College of American Pathologists (CAP) Accreditation by the Centers for Prevention and Disease Control (CDC) Contractor Qualification Requirements The pathologists for interpretive reports must have an unrestricted license to practice medicine in one of the states or territories of the United States of District of Columbia.

A division or subdivision of ophthalmologic pathology must exist within the medical center, with Ophthalmologic Pathologists on staff who have fellowship experience or other specialized training in eye pathology.

Expert consultant pathologists must have national reputations in their areas of specialization, as evidenced by ongoing publication in academic journals and/or presentations at national pathology meetings. Special attention will be paid to expertise in male genitourinary, soft tissue/bone, gastrointestinal, and pulmonary pathology. Sponsorship of subspecialty fellowships in adult surgical pathology, such as gastrointestinal, pulmonary, genitourinary, or bone and soft tissue fellowships, is also desirable.

The qualifications of such personnel shall also be subject to review by VA Medical Center Laboratory Director. VA reserves the right to approve the assignment of individual personnel furnished by the Contractor to perform the functions specified in the contract.

Test Sample Preparation The VA laboratory shall be responsible to provide laboratory specimens prepared in accordance with the contractor’s Laboratory User’s Manual. All specimens will be properly identified and labeled for testing. The contractor shall provide an adequate supply of requisition forms, special instructions and a current list of tests with reference ranges and specimen requirements. These requirements shall be defined in the laboratory user’s manual.

Transport of Specimens Vendor will work with the Minneapolis VA laboratory to arrange the transport of samples.

Turn Around Time Contractor shall provide a faxed report on anatomic pathology consultation cases within 4 working days of receipt of specimen, unless additional testing such as immunohistochemistry or molecular gene rearrangement studies is required.

Urinary histoplasma antigen shall be reported within 8 working days. Specialized neurological testing shall be reported within 14-17 working days.

Reporting of Test Results A report is defined as a printed final copy of pathology interpretive consult. Consult reports shall be sent by contractor to secured VAMC Laboratory FAX # 612-725-2079 located in the VAMC Pathology & Laboratory Medicine Service office. If results are telephoned prior to sending, the written report must include the name of the individual notified of the results, date and time of telephone report. Each consult report shall at a minimum indicate the following information:

Patient’s name and identification code Physician’s name (if supplied) VA Medical Center name Patient’s location, e.g. clinic, ward (if supplied) Test ordered Date/time of specimen collection (when available) Date/time specimen received in Reference Lab Date test completed Test result Flag abnormal results Reference Range Toxic and/or therapeutic range where applicable Name of testing laboratory (contractor and/or subcontractor) Testing laboratory specimen number Type of specimen Comments related to the test provided by the submitting lab Information that may indicate a questionable validity of test results Unsatisfactory specimen shall be reported with reason as to its unsuitability for testing Quality Control To ensure proper handling and test performance, the contractor shall provide the following updated information upon request during the life of the contract:

For quality purposes, tests routinely performed in duplicate should be indicated.

Coefficient of variation of quality control samples of all tests or specified tests the laboratory performs.

Proficiency testing data shall include a list of tests outside of the ± 2 SD range for the past two years. Contractor shall notify the laboratory of any test falling outside ± 2 SD range during the contract period.

Contractor shall provide address of processing sites under contract, including subcontracted testing location sites.

The contractor(s) facilities, methodologies (defined as the principal of the method and references), and quality control procedures may be examined by representatives of the VA at any time during the life of the contract.

Contractor agrees to maintain the minimum acceptable service, reporting systems and quality controls as specified herein. Immediate (within 24 hours) notification must be given to VA upon adverse action by a regulatory agency.

Testing Summaries Contractor shall provide the Minneapolis VA Laboratory a testing summary report each month following the month in which the testing service was provided. At the end of each contract year a cumulative (year-to-date) report shall be submitted to the VA providing the name of test ordered, price of test, cumulative totals and a total of all funds spent by that VA facility on laboratory testing services.

Testing Changes The Contractor shall advise the VA of any changes in assay methodology, procedures, reference ranges and any new tests introduced.

In the event that the contractor changes the assay procedures or a critically important component of an assay (e.g., an antibody, purified antigen, etc.) the contractor shall notify the VA Contracting Office and the VA Laboratory Director prior to the intended change. He shall provide documentation that the quality and efficacy of the test will remain unchanged or be improved.

Changes in the assay material, testing procedures or methodology that have not been reviewed and pre-approved by VA Laboratory Director and mutually agreed upon in writing between the contractor and the VA Contracting Officer, may be sufficient cause for the VA to use an alternate contractor for that specific test for the duration of the contract.

Contractor Telephone Numbers Contractor shall provide telephone number(s) and contact person(s) to be used by the VA Pathology & Laboratory Medicine Service for specimen inquiries, and Lab Technical/Pathologist consultation. There must be someone available at the number(s) provided at all times including weekends and holidays.

Phone Number Specimen Inquiries: __________________________

Lab Technical Director/Pathologists: __________________________

4. SUBCONTRACTING APPROVAL

If Contractor intends to use a subcontractor to provide any of the testing required under this contract, Contractor shall be responsible for finding a subcontractor laboratory with appropriate licensure and accreditation. Contractor shall notify the VA Contracting Office of any plan to use a subcontractor or make a subcontractor change, and request a prior acceptance and approval from VA.

Contractor will use the following subcontractor(s):

5. CHANGES

Changes in the terms and conditions of this contract may be made only by written agreement of both parties. Contractor must submit requests for changes in writing to the VA Contracting Office. Any and all modifications to this contract must be approved and prepared by the VA Contracting Officer for signature.

6. QUALITY ASSURANCE

The government will evaluate the Contractor’s performance under this contract and the Contractor performance will be monitored to determine if it meets the contract standards. A variety of methods may be used. Nonperformance or substandard task performance will be documented if and when it occurs. The Technical Representative will follow the methods of surveillance specified in the Performance Measures.

Performance Measures The following performance measures will be regularly tracked and monitored throughout the effective period of this contract by the Technical Representative and reported to the Contracting Officer. Acceptable performance on these measures, along with other factors, will be primary indices of contractor performance and a key consideration in contract renewal decisions.

Performance will be monitored using the following criteria:

Action/Test/Report
Turnaround time (TAT)
Acceptable Performance
Final surgical pathology consultation report completion
Within 4 working days of specimen receipt for cases not requiring additional studies.
80% of all consults submitted
Urinary histoplasma antigen result
Within 8 working days of specimen receipt.
80% of all tests submitted
Results of specialized neurology testing
Within 10-14 working days of specimen receipt.
80% of all tests

submitted

Molecular Testing
Within 7 working days of specimen receipt
80% of all tests

submitted

Government Roles and Responsibilities The MVAHCS Contracting Officer shall designate a Technical Representative to coordinate and monitor the work to be completed under this contract. Amy Colbaugh, COR has been designated as the representative to coordinate these services. Her contact information is listed below.

Technical Representative:

Amy Colbaugh, COR Minneapolis VA Health Care System One Veterans Drive, P&LMS (113) Minneapolis, MN 55417

(612) 467-5989 amy.colbaugh@va.gov

7. ORDERING PROCEDURES

This contract does not obligate any funding; therefore, the Contractor shall provide services under this contract only as directed in task orders. Task orders for bulk dollar amounts will be issued during the contract period. Any warranted VA Contracting Officer is authorized to issue task orders under this contract. The Minneapolis laboratory personnel may place verbal orders with the contractor to meet their testing needs, up to the bulk task order total. The contractor will be required to inform the VA contract specialist or contracting officer when each task order reaches 80% of the total bulk dollar amount.

In accordance with FAR 16.505, each task order will include the following: (i) Date of order (ii) Contract number and order number (iii) Contract item number and description, quantity, and unit price or estimated cost or fee (iv) Delivery or performance date (v) Place of delivery or performance (including consignee) (vi) Packaging, packing, and shipping instructions, if any (vii) Accounting and appropriation data (viii) Method of payment and payment office, if not specified in the contract (ix) Any other pertinent information.

VA Electronic Invoice Presentment and Payment System: The VA Financial Services Center (FSC) uses a third-party contractor, OB10, to transition vendors from paper to electronic invoice submission. Please go to this website: http://ob10.com/us/en/veterans-affairs-us/ to begin submitting electronic invoices, free of charge. Contact Tungsten/OB10 at the phone numbers or email listed below for assistance:

Tungsten/OB10 Support & setup Information: 1-877-489-6135 Tungsten/OB10 e-Invoice email: VA.Resgistration@tungsten-network.com Tungsten/OB10 Client Services: 1-877-752-0900, option 1

Contractor must furnish a designated point of contact for placing orders. Orders for laboratory testing services shall be sent to Contractor through the contact person listed below at the following address:

(Offeror to complete)

Vendor’s Contact Person: ____________________ Telephone Number: _______________ FAX Number: ______________ Address: _____________________

8. SAFETY AND SECURITY REQUIREMENTS

HIPAA Compliance and Requirements Contractor will adhere to the applicable provisions of Public Law 104-191, Health Insurance Portability and Accountability Act (HIPAA) of 1996 and the National Standards to Protect the Privacy and Security of Protected Health Information (PHI). As required by HIPAA, the Department of Health and Human Services (HHS) has promulgated rules governing the security, use and disclosure of protected health information by covered entities, including the Department of Veterans Affairs (VA). As defined in the Health Insurance Portability and Accountability Act (HIPAA) Public Law 104-191, your company may be required to execute a Business Associate Agreement.

If contractor’s facility is an entity that is not covered under the…

This is the start of the file's text. The full file is on GovTribe.

File details come from the government source that posted it.